199 related articles for article (PubMed ID: 25451351)
1. Personalized therapy for lung cancer.
Moreira AL; Eng J
Chest; 2014 Dec; 146(6):1649-1657. PubMed ID: 25451351
[TBL] [Abstract][Full Text] [Related]
2. Present and future molecular testing of lung carcinoma.
Dacic S; Nikiforova MN
Adv Anat Pathol; 2014 Mar; 21(2):94-9. PubMed ID: 24508692
[TBL] [Abstract][Full Text] [Related]
3. Successes and limitations of targeted cancer therapy in lung cancer.
Suda K; Mitsudomi T
Prog Tumor Res; 2014; 41():62-77. PubMed ID: 24727987
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations.
Milano GA
Chin Clin Oncol; 2015 Dec; 4(4):47. PubMed ID: 26730759
[TBL] [Abstract][Full Text] [Related]
5. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
6. Lung adenocarcinoma: lessons in translation from bench to bedside.
Sangodkar J; Katz S; Melville H; Narla G
Mt Sinai J Med; 2010; 77(6):597-605. PubMed ID: 21105123
[TBL] [Abstract][Full Text] [Related]
7. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.
Bronte G; Rizzo S; La Paglia L; Adamo V; Siragusa S; Ficorella C; Santini D; Bazan V; Colucci G; Gebbia N; Russo A
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S21-9. PubMed ID: 21129606
[TBL] [Abstract][Full Text] [Related]
8. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
[TBL] [Abstract][Full Text] [Related]
9. Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.
Masago K; Fujita S; Muraki M; Hata A; Okuda C; Otsuka K; Kaji R; Takeshita J; Kato R; Katakami N; Hirata Y
BMC Cancer; 2015 Nov; 15():908. PubMed ID: 26572169
[TBL] [Abstract][Full Text] [Related]
10. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
11. Personalized targeted therapy in advanced non-small cell lung cancer.
Ma PC
Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS56-60. PubMed ID: 22614968
[TBL] [Abstract][Full Text] [Related]
12. Personalized Therapy of Non-small Cell Lung Cancer (NSCLC).
Gadgeel SM
Adv Exp Med Biol; 2016; 890():203-22. PubMed ID: 26703806
[TBL] [Abstract][Full Text] [Related]
13. Resistance to Therapy.
Rivera G; Wakelee HA
Cancer Treat Res; 2016; 170():183-202. PubMed ID: 27535395
[TBL] [Abstract][Full Text] [Related]
14. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.
Thomas RK; Greulich H; Yuza Y; Lee JC; Tengs T; Feng W; Chen TH; Nickerson E; Simons J; Egholm M; Rothberg JM; Sellers WR; Meyerson ML
Cold Spring Harb Symp Quant Biol; 2005; 70():73-81. PubMed ID: 16869740
[TBL] [Abstract][Full Text] [Related]
15. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Balak MN; Gong Y; Riely GJ; Somwar R; Li AR; Zakowski MF; Chiang A; Yang G; Ouerfelli O; Kris MG; Ladanyi M; Miller VA; Pao W
Clin Cancer Res; 2006 Nov; 12(21):6494-501. PubMed ID: 17085664
[TBL] [Abstract][Full Text] [Related]
16. Clinical testing for molecular targets for personalized treatment in lung cancer.
Lam DC
Respirology; 2013 Feb; 18(2):233-7. PubMed ID: 22957484
[TBL] [Abstract][Full Text] [Related]
17. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.
Kruglyak KM; Lin E; Ong FS
Adv Exp Med Biol; 2016; 890():123-36. PubMed ID: 26703802
[TBL] [Abstract][Full Text] [Related]
18. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
Wu SG; Chang YL; Hsu YC; Wu JY; Yang CH; Yu CJ; Tsai MF; Shih JY; Yang PC
Oncologist; 2008 Dec; 13(12):1276-84. PubMed ID: 19060236
[TBL] [Abstract][Full Text] [Related]
19. [Personalized therapy of lung cancer - current standard and future challenges].
Riedel R; Wolf J
Dtsch Med Wochenschr; 2017 Nov; 142(22):1660-1668. PubMed ID: 29078211
[TBL] [Abstract][Full Text] [Related]
20. Lung cancer in the era of targeted therapy: a cytologist's perspective.
Zakowski MF
Arch Pathol Lab Med; 2013 Dec; 137(12):1816-21. PubMed ID: 23597048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]